Digital Health: what are the top startups?

Which clinical AI startups are doctors actually using now?

Abridge and OpenEvidence are the two clearest leaders right now.

Also, Ambience Healthcare, Nabla, Heidi Health, and Hippocratic AI are currently forming the strongest challenger group.

Abridge wins the enterprise-clinical-AI lane today because it has the best combination of health-system adoption, valuation momentum, and infrastructure credibility. In June 2025, it raised $300 million at a $5.3 billion valuation, only four months after being valued at $2.75 billion. That jump alone would not be enough.

What makes it stronger is the usage base: more than 150 health systems and an expected 50 million medical conversations supported in 2025. Then in June 2026, the Nvidia partnership added another layer. Abridge is no longer just “AI notes for doctors” but actually trying to become model infrastructure for clinical conversation.

OpenEvidence is the more explosive story. Its January 2026 round valued it at $12 billion, after reported valuations of about $1 billion in February 2025 and $6 billion in October 2025.

That is a crazy valuation jump, but the usage number makes it harder to dismiss: around 18 million clinical consultations from verified U.S. physicians in December 2025, versus about 3 million monthly consultations one year earlier.

Compared with Abridge, OpenEvidence is less about documenting the visit and more about becoming the doctor’s trusted clinical search layer. That is why both can lead at the same time. They sit next to different moments of the doctor’s workflow.

Ambience Healthcare is the strongest enterprise challenger because it is not fighting only on transcription quality. Its July 2025 $243 million Series C valued it at $1.25 billion, and the company is pushing into documentation, coding, and clinical documentation integrity.

Compared with Nabla or Heidi, Ambience looks more hospital-system-heavy and more tied to reimbursement workflows. That makes it less “bottom-up viral,” but potentially more defensible in large U.S. systems.

Nabla is the adoption challenger. Its June 2025 Series C brought total funding to $120 million, and the company said it was used by 130+ healthcare organizations and 85,000 clinicians. That is the interesting comparison: Nabla’s valuation signal is not as loud as Abridge’s, but its clinician footprint is real. It looks like a company that may be underpriced relative to usage.

Heidi Health is the fast international one. In October 2025, it raised $65 million at a $465 million valuation, only seven months after its Series A. Reports pointed to users across 116 countries and meaningful NHS adoption. Heidi is not yet in the same league as Abridge on U.S. enterprise depth, but these days it is one of the few scribe challengers that feels genuinely global rather than just “another ambient AI tool.”

Hippocratic AI is harder to rank because its bet is more ambitious and riskier. In November 2025, it raised $126 million at a $3.5 billion valuation, bringing total funding to about $404 million. The company is building patient-facing healthcare agents, which could be huge if it works.

But compared with Abridge or OpenEvidence, the proof is more forward-looking. We would call it a high-conviction moonshot, not the most proven clinical-AI leader yet.

If you want more recent data on this point, please see our latest digital health market report.

Which AI scribe startups are, today, more than just note-takers?

Abridge leads the AI scribe market, Ambience Healthcare is the best enterprise workflow challenger, Nabla has the clearest broad-clinician adoption signal, and Heidi Health is the one gaining fastest from below.

This category is already becoming brutal. A nice note-taking demo is not enough anymore. Epic, Microsoft, and every EHR-adjacent vendor can pressure the low end. The startups that matter now are the ones turning ambient notes into deeper clinical or financial workflow.

Abridge is still the front-runner because it has the broadest proof stack.

As seen above, it combines major health-system adoption, a sharp valuation reset upward, and a fresh Nvidia partnership. That mix is difficult for smaller scribes to match. If a CIO wants the safest “AI scribe at scale” choice today, Abridge is the name they will compare everyone else against.

Ambience looks like the better pick when the buyer cares about documentation and reimbursement together. Its positioning around coding and clinical documentation integrity gives it a sharper economic story than a pure time-saving tool.

That is the key distinction: Ambience does not need to win only by saying “doctors save time.” It can also say “documentation quality and coding quality improve,” which is closer to hospital CFO language.

Nabla is the company we would not underestimate. It does not have the same valuation headline as Abridge, but 85,000 clinicians is not a small number. Compared with Ambience, it feels more clinician-led and less revenue-cycle-led. That can be a strength if adoption keeps spreading through doctors before procurement committees slow everything down.

Heidi is the speed story. A $465 million valuation in October 2025 is far below Abridge, but that is partly the point. If Heidi keeps growing internationally while Abridge and Ambience fight the deepest U.S. enterprise battles, it could become the category’s strongest non-U.S.-centric winner.

The weaker names in this market are the ones still selling “we write the note.” That was exciting two years ago. Today, the bar is higher: distribution, clinical trust, workflow depth, and measurable savings.

Which startups are fixing the boring admin mess where hospitals lose money?

Tennr, Cohere Health, SmarterDx, CodaMetrix, Commure/Athelas, and Arbiter are the strongest names here, but they are not strong for the same reason.

Healthcare admin AI is probably one of the most monetizable parts of digital health right now. It is not sexy, but the buyer can see the problem: referrals get lost, authorizations get delayed, claims get undercoded, and staff burn hours moving information between systems.

Tennr is the clearest emerging referral-automation company. In June 2025, it raised $101 million in Series C funding and launched Tennr Network. The reason it stands out is focus. Many healthcare AI companies claim they can fix the back office. Tennr is attacking a very specific choke point: referrals that arrive through fax, email, portals, and messy documents. Compared with broader admin-AI tools, this focus makes the ROI easier to explain. If the patient referral never gets processed, the provider loses revenue before care even happens.

Cohere Health is stronger on scale. Its May 2025 $90 million Series C brought total funding to about $200 million, and the company has said it works with nearly 600,000 providers and processes more than 12 million prior-authorization requests annually. That puts Cohere in a different maturity bucket from Tennr. Tennr is the hotter emerging workflow bet; Cohere is closer to being a scaled infrastructure layer for prior authorization.

SmarterDx is probably the most interesting revenue-integrity company in the group. Its March 2025 $50 million raise was followed by the September 2025 acquisition of Pieces Technologies and the launch of SmarterNotes. That sequence matters. It suggests SmarterDx is trying to connect clinical notes with revenue intelligence, instead of staying inside one narrow coding workflow. Compared with CodaMetrix, SmarterDx feels more expansionary right now.

CodaMetrix is a real autonomous-coding leader, but the current signal is a little less fresh. The company has raised roughly $95 million since 2023, says it can reduce coding cost by up to 30%, became available in Epic Toolbox, and won a Mayo Clinic technology award. That is solid proof. But if we rank “what feels newly hot,” SmarterDx and Tennr are moving faster in the public signal layer.

Commure/Athelas is the high-scale, high-noise company in this group. In May 2026, it announced $70 million in financing at a $7 billion valuation. That is a major signal, especially with General Catalyst and Sequoia around the table. But there is also controversy around parts of the business, including the Strongline Pro injunction in 2025. So we should be precise: Commure is too large to ignore, but it is not the cleanest “best startup” story.

Arbiter is the one we would put on the watchlist rather than in the proven-leader group. A $52 million seed round at a $400 million valuation is unusual, especially with Michelle Carnahan’s background from Eli Lilly and Thirty Madison. The thesis, an AI operating spine for referrals, scheduling, and patient-data aggregation, fits exactly where the market is going. But today, the evidence is mostly founder quality and capital intensity, not deployed scale.

If you want more recent data on this point, please see our latest digital health market report.

Which mental health startups still look strong after the therapy-app hype faded?

Grow Therapy and Talkiatry look strongest right now, Headway and Spring Health remain major leaders, and Fay is the interesting adjacent specialist network.

Mental health is no longer about “download an app and talk to someone.”

The better companies now look more like insurance-covered provider networks, full-stack psychiatry groups, or employer platforms with measurable access. That change is healthy. It forces the market to prove care volume, payer coverage, and provider supply.

Grow Therapy has the freshest scale signal. In March 2026, it raised $150 million in Series D funding. Around that round, the company pointed to 10 million lifetime visits, 7 million visits in 2025 alone, more than 2 million patients served, and more than 100 insurance-plan partnerships. Compared with Headway, Grow currently feels like the faster “right now” story because the visit-volume signal is more recent and very concrete.

Talkiatry is the strongest psychiatry-specific company. In February 2026, it raised $210 million in Series D funding, bringing total funding above $400 million. It employs more than 800 full-time psychiatrists and has delivered about 3 million patient visits.

That comparison matters: Grow and Headway help match patients with covered therapists and providers, while Talkiatry owns more of the psychiatric supply. Psychiatry is harder to scale than therapy matching, so Talkiatry deserves a high rank even if the model is operationally heavier.

Headway remains one of the category anchors. Its July 2024 Series D valued it at $2.3 billion, and recent profiles showed more than 34,000 providers across all 50 states. Headway is still a leader, but it is less of a “new discovery” for this article. We should treat it as an established benchmark rather than spend too much space re-proving what the market already knows.

Spring Health is similar: still important, but not the freshest breakout.

Its $3.3 billion valuation in 2024 made it one of the biggest employer mental-health companies. Today, though, the more exciting signals are coming from companies with direct reimbursed visit volume or scarce provider supply. Employer mental health still matters, but it no longer feels like the hottest edge of the category.

Fay is worth adding because the same covered-network playbook is spreading into nutrition therapy. In February 2025, it raised $50 million in Series B funding and had more than 2,300 registered dietitians covered by major insurers. It is not a mental-health company in the narrow sense, but it overlaps with eating disorders, obesity, metabolic care, and behavioral health. Compared with pure wellness nutrition apps, Fay has a much stronger payer-backed model.

Which women’s health startups are actually breaking out now?

Midi Health is the breakout, Maven Clinic is the mature leader, Teal Health has the strongest regulatory signal, and Oula and Fay are the more specific bets.

Women’s health has had years of nice narratives and too few breakout companies. That is why Midi’s recent numbers matter. They are not just “women’s health is underfunded” talking points. They show a company turning a neglected clinical category into real volume.

Midi Health is clearly the hottest women’s health startup right now. In October 2025, reporting said it had raised $50 million in Series C funding and reached about $150 million in annual revenue run-rate, up from about $60 million at the end of 2024. In April 2026, reporting pointed to a $1 billion valuation and more than 20,000 women served per week. Compared with Maven, Midi is smaller historically but much fresher as a breakout. Compared with Oula, it has a cleaner scale signal. Compared with general telehealth, it owns a sharper wedge: midlife women’s health.

Maven Clinic is still the established category leader. Its October 2024 round valued it at $1.7 billion, and it has built a broad employer and payer footprint across fertility, maternity, parenting, and family health. But Maven is not the surprise. Everyone serious about women’s health already knows Maven. The newer question is whether Midi can become the next category-defining company, and the answer now looks much more like yes than it did two years ago.

Teal Health deserves a separate kind of respect. In May 2025, the FDA approved its at-home self-collection device for cervical cancer screening, making it the first at-home option of its kind in the U.S. That is not the same signal as revenue or valuation, but it may be more meaningful clinically. Teal is not trying to be a broad women’s health platform yet. It is opening a regulated screening category where access friction is real.

Oula is a more complicated watch. Its February 2024 $28 million Series B supported a hybrid maternity model combining midwifery and obstetrics. Strategically, that model makes sense because U.S. maternity care is expensive, fragmented, and often unpleasant for patients. But the company has also faced legal allegations around care quality, so we should not present it as a clean breakout without caution.

Fay comes back here because dietitian-led care fits many women’s health needs: pregnancy, menopause, PCOS, fertility, eating disorders, and metabolic care. It does not beat Midi on women’s health focus, but it may become an important covered specialist network underneath multiple women’s health journeys.

If you want more recent data on this point, please see our latest digital health market report.

Which obesity and metabolic startups can survive beyond the GLP-1 wave?

Omada Health is the most proven, Twin Health is the technical bet, knownwell is the emerging obesity-care specialist, and Function Health is the consumer-data wildcard.

The GLP-1 boom changed digital health because it created demand that software alone could not have created. The question now is which startups are building durable care around that demand, instead of just riding drug curiosity.

Omada Health is the most proven company in this category. It went public in June 2025 at about a $1.1 billion valuation, then reported $260 million in 2025 revenue, up 53%, and 886,000 total members at year-end, up 55%. It also said it had supported more than 150,000 members on GLP-1s, versus more than 50,000 at the end of 2024. Compared with newer obesity startups, Omada has a boring advantage: employer and payer distribution already exist. That makes it much better positioned to attach GLP-1 support to chronic-care programs.

Twin Health is more technically ambitious. In August 2025, it raised $53 million in Series E funding, reportedly nearing a $1 billion valuation. Its digital-twin model aims to personalize metabolic care using continuous data. Compared with Omada, Twin is less commercially proven at public scale, but its clinical-technology angle is more differentiated. If the market rewards deeper metabolic personalization, Twin could matter a lot.

knownwell is the emerging obesity-care company we would track closely. In October 2025, it raised $25 million in strategic-led financing led by CVS Health Ventures, with Intermountain Ventures, MassMutual Catalyst Fund, a16z Bio + Health, and Flare Capital also involved. That investor mix is the signal. Obesity care needs payer, provider, employer, and pharmacy-channel credibility. knownwell does not yet have Omada’s scale, but it has the right strategic backers for the market it is entering.

Function Health is not an obesity company, but it belongs in this conversation because it is trying to make lab data and preventive health feel consumer-native.

In November 2025, it raised $298 million at a $2.5 billion valuation. That is a huge round for a testing-and-health-data company. Compared with Omada and Twin, Function has less proof that it improves metabolic outcomes. But as a consumer-demand signal, it is one of the strongest in digital health today.

Found remains relevant, but the recent public signals are less sharp. It helped define consumer weight-care programs and expanded GLP-1 access, yet it does not currently show the same level of fresh financing, public revenue, or strategic backing as the companies above. We would keep it in the market map, but not in the top tier right now.

Which value-based care startups still feel like real platforms?

Strive Health and Aledade are the strongest platform stories, Cityblock is scaled but harder to read, and Author Health is the early specialized bet.

Value-based care is easy to talk about and hard to execute. The companies that matter are the ones taking on care coordination, medical cost, provider behavior, or patient outcomes at real scale. In this category, fluffy digital engagement metrics are almost useless.

Strive Health is the freshest standout. In September 2025, it raised $550 million, split between $300 million in equity and $250 million in debt. The round reportedly lifted Strive’s valuation to $1.8 billion. More importantly, the company had more than 145,000 kidney-disease patients, more than 6,500 provider partners across all 50 states, and nearly $5 billion in annual medical spend under management. Compared with most specialty-care startups, that is a serious scale profile. Kidney care is also a strong value-based category because the cost problem is large and concentrated.

Aledade is the older, more established winner. Its December 2025 $500 million credit facility, expandable to $650 million, gave it more firepower after years of growth. The company had already reported more than 1,500 practices across 45 states and D.C., more than 2 million patients, and $1.7 billion in healthcare-system savings through 2022. Compared with Strive, Aledade is broader and more mature. Strive feels hotter today; Aledade feels more like durable infrastructure.

Cityblock Health is big, but we should be careful. Recent reporting pointed to more than $1 billion in annual recurring revenue, over 100,000 Medicaid and dual-eligible members, and more than $800 million raised. That is real scale. The reason we do not rank it cleanly above Strive or Aledade is the model complexity. Medicaid and dual-eligible care is operationally intense, politically exposed, and difficult to standardize. Cityblock may be one of the most important companies in the space, but it is not the easiest “winner” to underwrite from outside.

Author Health is the specialized watch. It launched in 2023 with $115 million to serve Medicare Advantage members with serious mental illness and substance-use disorders. That is a massive unmet need and a high-cost population. Still, the latest public scale data is thinner than Strive’s or Aledade’s, so the honest ranking is: very interesting, not yet proven at the same level.

If you want more recent data on this point, please see our latest digital health market report.

Which consumer health startups are more than wellness brands?

Oura and Function Health are the strongest current signals, Whoop is still huge but noisier, Teal Health is the regulated-health outlier, and Levels has lost some freshness.

Consumer health is full of beautiful dashboards that do not change outcomes. So we have to be strict. The startups that matter need at least one of three things: large paid demand, medical-grade ambition, or regulatory proof.

Oura has the best consumer-health scale signal right now. In October 2025, it raised more than $900 million, with reports placing valuation around $11 billion. In May 2026, reporting said it had sold 5.5 million rings globally, had about 5 million paying subscribers, and reached $1 billion in 2025 revenue. Compared with Whoop, Oura feels more like a general health platform and less like an athlete-performance brand. Its move toward FDA clearance for blood-pressure features also makes the medical direction clearer.

Function Health is the biggest breakout in consumer diagnostics. Its November 2025 $298 million round at a $2.5 billion valuation is one of the strongest consumer-health financing signals of the past year. The company promotes a membership with more than 160 lab tests, body scans, and AI interpretation, and reporting said members had completed tens of millions of lab tests since 2023. Compared with Oura, Function is less continuous and more episodic. But it is attacking a different behavior: people want a deeper snapshot of their health than the traditional annual physical gives them.

Whoop is still very large. In March 2026, it raised $575 million at a $10.1 billion valuation and had more than 2.5 million members. The reason we rank it slightly below Oura for this article is not size. It is signal quality. Whoop has had more regulatory noise around blood-pressure features, while Oura currently looks cleaner as a health-platform story.

Teal Health is smaller, but its FDA signal is stronger than most consumer-health claims. At-home cervical cancer screening is not “wellness” but rather regulated preventive care. That makes Teal one of the few consumer-access startups with a concrete medical gate crossed.

Levels is a pioneer in CGM-based metabolic feedback, but the public signal is less fresh. It remains part of the category’s history, and it helped popularize metabolic tracking. Today, Function and Oura are simply showing stronger current momentum.

Which virtual-care companies proved public investors still care?

Hinge Health and Omada Health are the two proof points, and the lesson is pretty clear: virtual care still works when the company has revenue, outcomes logic, and better economics.

This is where many older digital-health stories get exposed. “We deliver care online” is not enough anymore. Public investors have been more willing to reward companies that show scale, revenue growth, and a path toward profitability.

Hinge Health is the strongest MSK proof point. It went public in May 2025, raised roughly $273 million, and traded above its IPO price on the first day. Before the IPO, it reported $390 million in 2024 revenue, up 33%, while narrowing net losses to $11.9 million from $108.1 million in 2023. In Q2 2025, revenue rose 55% year over year to $139.1 million, and the company guided to roughly $548 million to $552 million in 2025 revenue. Compared with most virtual-care companies, Hinge had a cleaner IPO story because MSK is expensive, employer-relevant, and measurable.

Omada is the chronic-care counterpart. As pointed out above, its 2025 revenue growth and member growth show that chronic-care platforms can still compound if they attach themselves to large employer and payer needs. Omada also did something smart: it connected diabetes, hypertension, and weight care to the GLP-1 moment instead of pretending the drug wave did not change the market.

Which digital health startups are rising fastest right now, not just already famous?

OpenEvidence, Midi Health, Tennr, Heidi Health, knownwell, Function Health, Fay, and Arbiter are the names that feel most “watch this now.”

This is probably the most valuable lens because the obvious leaders are already obvious. Abridge, Maven, Headway, Aledade, Hinge, Omada, and Oura are known winners. The better question is which companies have changed status recently.

OpenEvidence is the fastest-rising company by valuation and usage. As we saw previously, its jump to a $12 billion valuation would look absurd without the physician-consultation volume behind it. With that usage signal, it becomes one of the strongest “something changed here” stories in the whole market.

Midi Health is the cleanest women’s health breakout. Revenue run-rate reportedly moving from about $60 million at the end of 2024 to about $150 million in 2025 is not a soft signal. Add the 2026 valuation and weekly patient volume, and we can say pretty clearly that Midi has crossed from niche startup into category leader candidate.

Tennr is the most interesting emerging admin-AI startup because referrals are so specific and so painful. A company solving a narrow workflow can often sell faster than a company promising to “fix healthcare operations.” Tennr’s round size says investors believe that wedge can be big.

Heidi Health is the ambient-AI challenger with the best speed signal. It is not beating Abridge in U.S. enterprise proof today, but it is moving fast internationally and has a much lower valuation base. That combination can make it one of the better asymmetric bets in the category.

knownwell is the obesity-care specialist to watch. The CVS-led strategic round matters because obesity care will be won through channels, not just brand. If knownwell converts those relationships into payer and provider distribution, it becomes much more than another GLP-1 clinic.

Function Health is the consumer-diagnostics breakout. The round size and valuation show unusual demand for deep health testing. The next question is outcomes, but we do not need to pretend the demand signal is weak. It is not.

Fay is a quieter but smart bet. Insurance-covered nutrition therapy is not a glamorous category, yet it connects to obesity, women’s health, eating disorders, fertility, and metabolic care. Its dietitian network gives it a more durable model than most nutrition apps.

Arbiter is the earliest-stage name on this list. It does not have the customer proof yet, but the $52 million seed round, $400 million valuation, and founder background make it worth watching. We would not call it a leader today. We would call it one of the more serious “next wave” bets.

If you want more recent data on this point, please see our latest digital health market report.

So which digital health startups are actually the top ones?

The strongest digital health startups right now are Abridge, OpenEvidence, Ambience Healthcare, Grow Therapy, Talkiatry, Midi Health, Tennr, Cohere Health, Strive Health, Aledade, Omada Health, Hinge Health, Oura, Function Health, and Maven Clinic.

That conclusion comes from aggregating the categories, not from choosing one lazy definition of “top.” A company can be top because it has the most usage, the fastest valuation expansion, the strongest regulatory signal, the best public-market proof, the deepest provider network, or the clearest workflow ROI. The best names show more than one of those signals.

Abridge is the most complete clinical-AI startup. OpenEvidence is the fastest-rising doctor-facing AI company. Ambience is the most credible documentation-to-revenue-cycle challenger. Grow Therapy and Talkiatry are the strongest mental-health care-access stories today because they show real visit volume and provider supply. Midi Health is the breakout women’s health company. Tennr and Cohere show that admin AI may become one of the most financially attractive parts of digital health. Strive and Aledade are the value-based care platforms with the clearest scale proof. Omada and Hinge show that digital health can still reach public-market validation. Oura and Function Health show that consumer health is still alive when demand is paid, frequent, and data-rich. Maven remains a core women-and-family health leader, even if the freshest breakout energy is currently around Midi.

The emerging list is where we would spend the most attention now: OpenEvidence, Midi, Tennr, Heidi, knownwell, Function, Fay, and Arbiter.

These are the companies where recent signals changed the story most.

Category	Startups selected and why
Clinical AI doctors use	Abridge leads on enterprise adoption and infrastructure credibility; OpenEvidence leads on physician usage velocity; Ambience, Nabla, Heidi, and Hippocratic AI each win a different challenger lane.
AI scribes beyond notes	Abridge is the default enterprise benchmark; Ambience is stronger on documentation-to-revenue workflow; Nabla wins on broad clinician adoption; Heidi is the fast global challenger.
Healthcare admin AI	Tennr is the hottest referral-automation wedge; Cohere has prior-authorization scale; SmarterDx is pushing revenue integrity wider; CodaMetrix is the coding leader; Commure is large but noisy; Arbiter is the early watch.
Mental health access	Grow Therapy has the freshest visit-volume signal; Talkiatry owns scarce psychiatry supply; Headway remains the provider-network benchmark; Spring Health stays important in employers; Fay extends the covered-network model into nutrition.
Women’s health	Midi is the breakout; Maven is the established platform; Teal has the strongest regulatory proof; Oula is a maternity-care watch with caveats; Fay is relevant across women’s nutrition needs.
Obesity and metabolic care	Omada is the proven public company; Twin is the technical metabolic bet; knownwell has the strongest emerging strategic backing; Function is the consumer-data wildcard; Found remains relevant but less fresh.
Value-based care	Strive is the freshest specialty-care platform; Aledade is the durable primary-care infrastructure; Cityblock has scale but higher complexity; Author Health is the specialized early bet.
Consumer diagnostics and wearables	Oura has the strongest consumer scale; Function is the diagnostics breakout; Whoop is huge but noisier; Teal is the regulated-health outlier; Levels is a pioneer with less current momentum.
Public-market proof	Hinge Health proves virtual MSK can work publicly; Omada proves chronic-care platforms can still grow if tied to employer, payer, and GLP-1 demand.
Fastest emerging names	OpenEvidence, Midi, Tennr, Heidi, knownwell, Function, Fay, and Arbiter have the freshest signals that changed how we should rank them.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.